4.7 Article

Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 69, Issue 4, Pages 730-732

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/ard.2009.108456

Keywords

-

Categories

Funding

  1. EULAR
  2. Netherlands Organisation for Health Research and Development
  3. Dutch Arthritis Association
  4. European Commission

Ask authors/readers for more resources

Objectives To evaluates the diagnostic performance of the anti-CCP2, anti-CCP3 and anti-mutated citrullinated vimentin (anti-MCV) tests in differentiating rheumatoid arthritis (RA) from other forms of arthritis in a clinical setting of early arthritis. Methods In 917 patients with recent-onset arthritis (566 RA, 351 other diseases) and in 99 healthy controls the anti-MCV, anti-CCP2 and anti-CCP3.1 tests were performed and the test characteristics compared. Results Comparison of the tests for differentiating RA from other causes of arthritis showed a lower specificity for anti-MCV (82.9%) than for anti-CCP2 (93.4%) and anti-CCP3.1 (90.0%). Similarly, the positive likelihood ratio for anti-MCV was also lower (3.6, compared with 8.7, 5.8 for anti-CCP2 and anti-CCP3.1). The anti-MCV test had a higher sensitivity (62% vs 56.9% and 58.1%, respectively). In psoriatic arthritis, spondyloarthropathy and other arthritis anti-MCV antibodies had a prevalence of 15.2%, 13.9% and 19.4%. Conclusion The diagnostic performance of the antitest in the differential diagnosis of early arthritis is lower than that of the anti-CCP tests.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available